PGGM Investments grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 22.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 243,486 shares of the medical research company’s stock after buying an additional 44,788 shares during the quarter. PGGM Investments’ holdings in IQVIA were worth $54,884,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the period. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at about $27,000. Westside Investment Management Inc. boosted its stake in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC purchased a new position in shares of IQVIA in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Analysts Set New Price Targets
IQV has been the topic of several research analyst reports. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and raised their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Morgan Stanley set a $225.00 target price on IQVIA in a research report on Thursday, May 7th. Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Finally, Truist Financial dropped their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Buy” and an average price target of $225.69.
IQVIA Trading Up 0.2%
NYSE:IQV opened at $168.28 on Tuesday. The stock’s 50 day moving average price is $169.83 and its 200 day moving average price is $197.14. The company has a market capitalization of $28.09 billion, a PE ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Recommended Stories
- Five stocks we like better than IQVIA
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
